Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

[1]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[2]  N. Young,et al.  Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia , 2006, British journal of haematology.

[3]  N. Young,et al.  Treatment of severe aplastic anaemia with combined immunosuppression: anti‐thymocyte globulin, ciclosporin and mycophenolate mofetil , 2006, British journal of haematology.

[4]  N. Young,et al.  In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR β-CDR3 sequencing , 2004, The Lancet.

[5]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[6]  H. Heimpel,et al.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. , 2003, Blood.

[7]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[8]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[9]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[10]  N. Young.  Acquired Aplastic Anemia , 2002, Annals of Internal Medicine.

[11]  E. Gordon-Smith,et al.  Views on the pathophysiology of aplastic anaemia , 2002, International journal of hematology.

[12]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[13]  J. Bennett,et al.  World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.

[14]  F. Rodeghiero,et al.  Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy , 1999, British journal of haematology.

[15]  N. Young,et al.  Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure Syndromes , 1999, Annals of Internal Medicine.

[16]  P F Thall,et al.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998, Statistics in medicine.

[17]  A. Gratwohl,et al.  Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia , 1998, British journal of haematology.

[18]  N. Young,et al.  The pathophysiology of acquired aplastic anemia. , 1997, The New England journal of medicine.

[19]  N. Young,et al.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. , 1995, Blood.

[20]  F. Locatelli,et al.  Antilymphocyte globulin, cyclosporin, and granulocyte colony- stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party , 1995 .

[21]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[22]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[23]  J. Marsh.  Making therapeutic decisions in adults with aplastic anemia. , 2006, Hematology. American Society of Hematology. Education Program.

[24]  B. Johansson,et al.  Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. , 2006, Haematologica.

[25]  F. Locatelli,et al.  Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. , 2004, Haematologica.

[26]  Y. Saunthararajah,et al.  Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? , 2000, Seminars in hematology.

[27]  P F Thall,et al.  New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.